Disordered proteins are challenging therapeutic targets, and no drug is currently in clinical use that has been shown to modify the properties of their monomeric states. Here, we identify a small molecule capable of binding and sequestering the amyloid-β peptide (Aβ) in its monomeric, soluble state. Our analysis reveals that this compound interacts with Aβ and inhibits both the primary and secondary nucleation pathways in its aggregation process. We characterise this interaction using biophysical experiments and integrative structural ensemble determination methods. We thus observe that this small molecule has the remarkable effect of increasing the conformational entropy of monomeric Aβ while decreasing its hydrophobic surface area. We then show that this small molecule rescues a Caenorhabditis elegans model of Aβ-associated toxicity in a manner consistent with the mechanism of action identified from the in silico and in vitro studies. These results provide an illustration of the strategy of targeting the monomeric states of disordered proteins with small molecules to alter their behaviour for therapeutic purposes.
Introduction
Alzheimer's disease is a fatal neurodegenerative condition that affects over 50 million people worldwide, a number that is predicted to rise to 150 million by 2050 unless methods of prevention or treatment are found, with a cost to the global economy that exceeds one trillion dollars per year 1, 2 . Despite over 25 years of intensive research and hundreds of clinical trials, there is still no drug capable of modifying the course of this disease 1,2 .
The aggregation of the amyloid-β peptide (Aβ) in brain tissue is one of the hallmarks of Alzheimer's disease [3] [4] [5] [6] [7] . This process involves at least three forms of Aβ: (i) a monomeric state, which is highly disordered, (ii) oligomeric aggregates, which are heterogeneous, transient and cytotoxic, and (iii) fibrillar structures, which are ordered and relatively inert, although they are capable of catalysing the formation of Aβ oligomers 8, 9 . More generally, the aggregation of Aβ involves a complex non-linear network of inter-dependent microscopic processes, including: (1) primary nucleation, in which oligomers form from monomeric species, (2) elongation, in which oligomers and fibrils increase in size by monomer addition, (3) secondary nucleation, whereby the surfaces of fibrillar aggregates catalyse the formation of new oligomeric species, and (4) fragmentation, in which fibrils break into smaller pieces, increasing the total number of oligomers and fibrils capable of elongation 10, 11 .
Aβ is produced by proteolysis from the transmembrane amyloid precursor protein, and its 42residue form (Aβ42) is the predominant species in deposits characteristically observed in the brains of patients with Alzheimer's disease 6, 7, 12 . Kinetic analysis shows that, once a critical concentration of Aβ42 fibrils has been formed, secondary nucleation overtakes primary nucleation in becoming the major source of Aβ42 oligomers, as fibril surfaces act as catalytic sites for their formation 8 . The fact that the oligomers appear to be the most toxic species formed during the aggregation process [13] [14] [15] , however, suggests that therapeutic strategies targeting Aβ aggregation should not primarily aim at inhibiting fibril formation per se, but rather doing so in a manner that specifically reduces the generation of oligomeric species 16 . Complex feedback mechanisms between the different microscopic steps in the aggregation reaction can lead to an increase in the concentration of oligomers even when the formation of fibrils is inhibited, and hence result in an increase in pathogenicity 16 .
Using experimental and computational biophysical techniques and mathematical modelling, we characterise the interaction of the small molecule 10074-G5 (biphenyl-2-yl-(7-nitrobenzo [1, 2, 5] oxadiazol-4-yl)-amine, Figure 1a) , with Aβ42 in its disordered, monomeric state.
10074-G5 has been previously identified to inhibit c-Myc-Max heterodimerization 33 specifically by binding and stabilizing the intrinsically disordered c-Myc monomer 34, 35 . Here, we also observe that 10074-G5 binds monomeric Aβ42, a disordered peptide unrelated to c-Myc. As a result of this interaction, 10074-G5 significantly delays both primary and secondary nucleation pathways in Aβ42 aggregation. We characterise this interaction using biophysical experiments and integrative structural ensemble determination techniques, and observe that Aβ42 remains disordered in the bound form with decreased hydrophobicity. Notably, we also observe that the conformational entropy of Aβ42 increases upon interacting with 10074-G5, suggesting that exploiting this phenomenon may be a potential therapeutic strategy for disordered proteins. We further show that this molecule inhibits the pathogenesis associated with Aβ42 aggregation in a Caenorhabditis elegans model of Aβ42-mediated toxicity 36 in a manner consistent with the binding mechanism described in silico and characterised in vitro.
Results

Selection of the system
We selected the compound 10074-G5 as model system to understand whether and how a small molecule inhibits the aggregation of Aβ by binding the monomeric form of this peptide. We used this molecule as it has been reported to bind the oncogenic disordered protein c-Myc in its monomeric form, and it contains a nitrobenzofurazan moiety, which has been previously shown to inhibit the aggregation of Aβ 37 .
Characterisation of the binding of 10074-G5 to monomeric Aβ42
We characterised the binding of 10074-G5 with monomeric Aβ42 using a multidisciplinary approach based on experiments and integrative structural ensemble determination. First, we carried out bio-layer interferometry (BLI, see Materials and Methods) measurements to characterise this interaction in real-time. We immobilised N-terminally biotinylated monomeric Aβ42 on the surface of super streptavidin sensor tips (Materials and Methods) and exposed them to varying concentrations of the small molecule (Figure 1b) . We observed a concentrationdependent response, indicative of binding. By globally fitting the binding curves to simple one-step association and dissociation equations, such that the fit constrains all curves to share single association ( on ) and dissociation ( off ) rates, we determined on to be 1.5 x 10 3 ± 0.2 x 10 3 M -1 sec -1 and off to be 3.2 × 10 -2 ± 0.3 × 10 -2 sec -1 , corresponding to a binding dissociation constant ( D ) of 21 µM. This affinity value is comparable to other small molecule interactions with disordered proteins 34 .
We then investigated the binding of 10074-G5 and monomeric Aβ42 at the ensemble-averaged, single residue level. To do so, we performed 2D H N-BEST CON nuclear magnetic resonance (NMR) experiments 38 on uniformly 13 C, 15 N-labelled monomeric Aβ42 in the presence of 1-and 2-fold concentrations of 10074-G5. As monomeric Aβ42 is relatively stable in solution at low concentrations and temperatures, we examined the binding of 10074-G5 to monomeric Aβ42 under these conditions (20 µM of Aβ42 of at 5 °C). Minimal chemical shift perturbations were observed in the 2D H N-BEST CON spectra upon the addition of compound at a 2:1 ligand:protein ratio at 5 °C (Figure S1), consistent with other reports of small-molecule binders of disordered proteins 34, 39 , suggesting that Aβ42 remains disordered in the presence of 10074-G5. We then performed this experiment at 15 °C in the absence and presence of pre-saturation of the solvent.
This experiment, which relies on heteronuclear direct detection with minimal perturbation of proton polarization, provides a valuable tool to study solvent exposed systems in which amide protons experience fast hydrogen exchange 38 . In particular, the signals of amide nitrogen atoms become attenuated when their directly bound protons are in fast exchange with the solvent. After testing this on a well characterized protein (ubiquitin), we performed this experiment on Aβ42.
In the absence of 10074-G5, we observed that several hydrophobic residues, particularly Cterminal residues are protected from solvent exchange (Leu17, Leu34, Val36, Ile41, Ala42, see I/I0 values as shown in Figure 1c,d) . Notably, in the presence of 10074-G5, we observed the quenching of several residues across the sequence of the monomeric Aβ42 peptide that were not quenched in the absence of 10074-G5 (Figure 1c,d ), suggesting that some residues have increased solvent exposure in the presence of the small molecule. This change in the solvent exchange profile suggests that 10074-G5 interacts with monomeric Aβ42 in a manner that increases the solubility of at least some of the conformations within the monomeric structural ensemble 29, 30 .
To obtain further insight into the thermodynamic properties of this interaction, we quantified the heat changes upon 10074-G5 binding to Aβ40 using isothermal titration calorimetry methods ( Figure S2 ). In these experiments, we used Aβ40 instead of Aβ42 because of the higher solubility of Aβ40; we have, however, shown that 10074-G5 has similar effects on the aggregation of Aβ40 as on that of Aβ42 ( Figure S3a ). The observation of minimal heat changes ( Figure S2 ) suggests that the interaction of 10074-G5 with monomeric Ab is likely to be entropic, as found for the interactions of another small-molecule with a disordered peptide 40 .
To obtain a structural description of how 10074-G5 affects the disordered structural ensemble of Aβ42, we employed metadynamic metainference, an integrative structural ensemble determination approach 41, 42 that combines all-atom molecular dynamics simulations with NMR chemical shift data to improve force field accuracy (see Materials and Methods, Figures 2 and S4-8). These simulations reveal that Aβ42 remains disordered in the form bound to 10074-G5, retaining several ensemble-averaged properties. In particular, we noted that most average interresidue contacts of the unbound peptide remain the same in the bound form (Figure 2a ).
Furthermore, the radii of gyration of the bound and unbound forms of the peptide are also highly similar (Figure 2b) . The presence of 10074-G5 does, however, alter the conformational ensemble of Aβ42, promoting conformations with lower relative hydrophobic surface area (the fraction of accessible hydrophobic surface area with respect to the total accessible surface area,
Figure 2c).
To determine which residues became more exposed or protected in the presence of 10074-G5, we compared the residue-specific average solvent accessible surface areas per residue in the presence and absence of 10074-G5. Notably, we observe that Lys34 and Met35 become more protected in the presence of the small molecule. Met35 has previously been identified as a key residue for attention of aggregation, as oxidation has been shown to reduce the lag time of primary nucleation 43 .
The decrease in the hydrophobic surface area is confirmed by the calculation of the average number of hydrogen bonds formed by water molecules within the hydration shell (all waters within 0.4 nm of Aβ42). We found that water molecules form 3.075(1) hydrogen bonds on average in the absence of 10074-G5, a number that increases in its presence to 3.096(1), getting closer to the bulk-like value of 3.448(1) under the conditions investigated here; errors are calculated comparing the first and second halves of the trajectories (Figure S6a) 44 . As expected, we observed instead no difference between the average number of hydrogen bonds formed by water molecules in the bulk between the apo and holo simulations ( Figure S6b ). To determine whether or not this binding could be characterised by the release of water molecules upon association, we calculated the average number of water molecules in the hydration shell and show that this value is similar with and without association ( Figure S6c) .
To structurally characterise the unbound and bound conformations of Aβ42 and assess convergence, we performed a clustering analysis (Figures S7, S8 ). We observed that while 10074-G5 binds the extended form in a non-specific manner, all other structural clusters show localisation of the compound within well-defined pockets of Aβ42 for specific conformations (Figure 2c and S7a) involving hydrophobic, hydrophilic, charged, and polar residues ( Figure   S8 ). Interestingly, we also observed that the conformational entropy of Aβ42 is increased in the bound form, exhibiting the so-called "entropic expansion" mechanism which may contribute favourably to the binding free energy 29 (Figure S7c) . In stark contrast to the "lock and key" binding mechanism, this observation suggests that the identification of small molecules which increase the conformational entropy of the disordered proteins may be a promising therapeutic strategy.
To probe the energetic contributions to this interaction on an ensemble-averaged, residuespecific level, we analysed Lennard-Jones and Coulomb contributions between 10074-G5 and each residue. We observe strong Lennard-Jones interactions, particularly between aromatic residues (Figure 2e ) Tyr10, Phe19 and Phe 20 and 10074-G5. The strongest Coulomb interactions occur at charged residues Lys16 and Lys28 (Figure 2e ).
The small molecule 10074-G5 sequesters monomeric Aβ42 and inhibits its aggregation
We measured the kinetics of Aβ42 aggregation at a concentration of 1 µM in the presence and absence of increasing concentrations of 10074-G5. Measurements were performed by means of a fluorescent assay based on the amyloid-specific dye thioflavin-T (ThT), which reports on the overall fibril mass formed during the aggregation process 5, 8, 16, [45] [46] [47] . We found that 10074-G5 has a significant effect on Aβ42 aggregation (Figure 3a,b) . Specifically, the data show that the final value of the ThT fluorescence, which corresponds to the end point of the aggregation reaction, is dependent on the concentration of the compound (Figure 3a) . The observation of a significant decrease in the final ThT intensity could be due to several non-mutually exclusive possibilities including: 1) interference of the ThT signal by 10074-G5, 2) formation of soluble off-pathway aggregates, 3) sequestration of Aβ42 during the aggregation process 18 .
Given the fact that 10074-G5 is a coloured compound, we sought to investigate whether the decrease in the fluorescence intensity of ThT was exclusively due to an interference of 10074-G5 with the dye, or also due to a decrease in the mass of the fibrils formed during the aggregation process. To this end, we performed a ThT-independent dot-blot assay in which we explicitly measured the quantity of soluble Aβ42 over time in the presence and absence of 10074-G5 using the W0-2 antibody, which binds to Aβ (Figure 3c-e ). The solubility was determined by measuring the amount of Aβ42 that did not sediment after 1 h of ultracentrifugation at 100,000 rpm. We observed that in the presence of a 20-fold excess of 10074-G5, approximately 40% of the total amount of Aβ42 remained in a soluble form (Figure 3d,e) . These experiments indicate that not all Aβ42 monomers are incorporated in ThT-binding fibrils at the end of the aggregation process, and, thus, that the presence of 10074-G5 sequesters Aβ42 in its soluble form. 48 . This experiment reports on early aggregation events that may be invisible to ThT, which is specific for cross-β sheet content as early aggregates such as oligomers or multimers may lack β-sheet structure. 49 We observed, however that in the presence of an equimolar concentration of 10074-G5, the fluorescence intensity remains constant over time (Figure 3g) , thereby suggesting that Aβ42 does not self-associate in the presence of 10074-G5.
To further demonstrate that 10074-G5 alters the kinetics of aggregation, we performed 3-D morphological analyses of fibrils using high resolution and phase-controlled 50 atomic force microscopy (AFM) on the time scale of the aggregation process (Figures 3b and S9) . Singlemolecule statistical analysis of the aggregates in the 3-D maps shows that Aβ42, both in the absence and presence of 10074-G5, forms non-mature aggregates with average cross-sectional diameters of approximately 2-3 nm, and mature fibrillar aggregates with average diameters of approximately 5-6 nm, as previously observed 51, 52 . It has been previously shown that fibrillar species with diameters less than 6 nm lack a cross-b sheet structure fully stabilised by a tight network of intermolecular hydrogen bonding, as compared to mature fibrillar aggregates 51 .
Notably, we observed that at the same time point of aggregation, the fibrillar aggregates formed in the presence of 10074-G5 had smaller cross-sectional diameters than those formed in its absence, with a significantly higher abundance of non-mature species with respect to mature fibrillar species. These data suggest that the process of fibril formation and maturation of crossb sheet structure in the presence of this compound is considerably slower than in its absence 52, 53 (Figures 3b and S9b).
10047-G5 does not chemically modify Aβ42
To determine whether or not the binding of 10074-G5 to Aβ42 is covalent or induces other chemical modifications, we performed mass spectrometry on Aβ42 incubated in the presence and absence of 10074-G5. Samples were incubated overnight at 37 °C and then spun down using an ultracentrifuge (Materials and Methods). The supernatant and resuspended pellet of the aggregation reactions were analysed by matrix assisted laser desorption/ionization (MALDI) mass spectrometry (Figure S10). No mass increase was observed following the incubation with 10074-G5, indicating that its presence does not result in detectable covalent chemical modifications to Aβ42.
10074-G5 inhibits all microscopic steps of Aβ42 aggregation
In order to better understand the mechanism of inhibition of Aβ42 aggregation by 10074-G5, we performed a kinetic analysis on the ThT aggregation traces. Figure 4a shows the ThT kinetic curves normalized relative to the reaction end points. From the normalized data, we observe that 10074-G5 slows down the aggregation reaction in a concentration-dependent manner, consistent with the AFM and dot blot results, confirming a delay in the aggregation process of Aβ42 ( Figure S9) . We then used a chemical kinetics approach 54 to determine whether the inhibition data could be explained by a monomer sequestration model, in which 10074-G5 inhibits Ab42 aggregation by binding monomeric Ab42 and, in this manner, reduces the concentration of monomers available for each microscopic step of aggregation (see SI). Specifically, we first fitted the measured aggregation kinetics in the absence of 10074-G5 to a kinetic model of Ab42 aggregation (see SI, Eq. S10) 54 to estimate the values of the unperturbed rates for primary nucleation, elongation, and secondary nucleation. We then formulated a master equation model for inhibited aggregation kinetics in the presence of 10074-G5 (Eq. S11). We derived explicit integrated rate laws describing inhibited kinetics (Eqs. S11-14 and Figure S11 ), which we used to fit the experimental ThT data in the presence of 10074-G5. For this analysis, we implemented the unperturbed rate constants for aggregation, leaving the value ofas the only fitting parameter. We performed a global fit; all ThT profiles at increasing concentrations of 10074-G5 were not fit individually, but rather using the same choice of -, with the dependence on the concentration of 10074-G5 being captured in the integrated rate law through Eq. S14. The result of this global fit is shown in Figure 4a and yields an affinity value of -= 40 µM, consistent with other affinities reported for small molecule binders of disordered proteins 34 . It is interesting to note that this estimated affinity is considerably weaker than small molecule binders of structured proteins, which are often in the nM range. It may seem that such a weak binder of Ab would have little inhibitory effects. However, we note that the level of inhibition in general depends not on the absolute value of . , but on the combined parameter . /[ ], where [C] is the drug concentration, provided that the rate of binding ( 34 [ ]) is sufficiently fast as compared to the overall timescale of aggregation ( ) 55 . Therefore, it is possible to have effective inhibition even for small molecules with . values in the µM range, provided that [ ] is on the same order of magnitude as . (see Figure S12 ).
The analysis of experimental aggregation data in the presence of increasing concentrations of inhibitor using our integrated rate law thus yields an independent method for determining the binding constant of 10074-G5 to the monomers. To provide further support to this analysis, we varied the concentration of monomeric Aβ42 (1, 1.5 and 2 µM) and recorded kinetic traces of aggregation in the absence (Figure 4b ) and presence of 10 µM 10074-G5 (Figure 4c ). Using the rate parameters determined from the uninhibited kinetics and the same value ofobtained from the global fit shown in Figure 4a , we find that the time course of aggregation predicted by our monomer sequestration model are in good agreement with the independent experimental data (Figure 4c) .
A key prediction from the monomer sequestration model is that a monomer-interacting compound should interfere with all three microscopic steps of aggregation. In fact, we find that the presence of an inhibitor that binds monomers quickly compared to the overall aggregation rate does not affect the topology of the reaction network. As a result, the inhibited kinetics can be interpreted in terms of effective rates of aggregation that depend on the concentration of inhibitor (Eq. S14). In Figure 4d , we show the values of the effective rates of aggregate proliferation through primary (λ) and secondary (κ) nucleation pathways as a function of the concentration of 10074-G5 predicted by this model (see Eq. S10 for a definition of λ and κ). The monomer sequestration model also predicts that the effective rate of elongation should be reduced (Figure S13b) , although to a lesser extent than the nucleation pathways, which have a stronger monomer concentration dependence. To test this prediction, we performed seeded aggregation experiments in the presence of preformed Aβ42 fibrils to obtain independent measurements of the effective elongation rate as a function of 10074-G5 concentration. We observed that 10074-G5 indeed decreases the effective rate of fibril elongation (Figure S13a) , consistent with the monomer sequestration mechanism.
We also sought to understand whether 10074-G5 binds monomeric Aβ40 with a comparable affinity to that of Aβ42. To address this question, we applied the monomer sequestration model as used in Figure 4a , to fit the inhibitory effects of 10074-G5 on aggregation of 10 µM of Aβ40 ( Figure S3a) . From this analysis, we extracted an affinity constant of 10074-G5 for Aβ40 of 10 µM, a similar value to that obtained for Aβ42 ( Figure S3b) . Given the increased toxicity of Aβ42 as compared to Aβ40, we anticipate the optimisation of small molecules more specific for monomeric Aβ42 over Aβ40.
Characterisation of the binding of 10074-G5 to stabilised Aβ40 oligomers
Next, we probed whether 10074-G5 alters the behaviour of oligomeric species of Aβ. Although it is extremely challenging to determine whether 10074-G5 modifies the oligomeric intermediates of Aβ42 formed on-pathway to aggregation, which are transient, heterogenous species, it is possible to carry out this analysis more readily on oligomers of Aβ40 stabilised using Zn 2+ 56 . Thus, we next considered whether or not 10074-G5 can alter the behaviour of these stabilised, pre-formed oligomeric species. We incubated pre-formed oligomers in the presence of 10074-G5, centrifuged the samples, and measured the quantities of Aβ40 in the pellet and in the supernatant by using SDS-polyacrylamide gel electrophoresis (SDS-PAGE, Figure S14a ).
The results indicate that these pre-formed oligomers did not dissociate in the presence of 10074-G5. Furthermore, 10074-G5 was found not to alter the turbidity of solutions in which they were present as measured by their absorbance profiles ( Figure S14b) suggesting that 10074-G5 does not cause such species to change detectably in size. Lastly, dot blots of pre-formed oligomeric samples in the presence and absence of the compound using the OC-antibody, which binds to βsheets 57 , show that the oligomers maintain their characteristic conformations (Figure S14c) . Due to the coloured nature of 10074-G5, it was neither possible to characterise the oligomers in the presence of the compound with dynamic light scattering nor analytical ultracentrifugation measurements. Taken together, these data suggest that 10074-G5 does not disaggregate the preformed oligomeric species or cause them to undergo further assembly. Nevertheless, it remains possible that this compound affects the evolution of oligomer populations formed during the aggregation reaction, potentially inhibiting their conversion into fibril-competent species.
10074-G5 inhibits Aβ42 aggregation in a C. elegans model of Alzheimer's disease
To determine if 10074-G5 can inhibit the formation of Aβ42 aggregates in vivo, we tested its effects using a C. elegans model of Aβ42-related toxicity (GMC101, Figures 5, S15, S16) , in which age-progressive paralysis was induced by overexpression of Aβ42 in the body wall muscle cells 36 . The N2 wild-type strain 58 was used as a control.
10074-G5 was administered to worms from larval stage L4, and then continuously throughout their lifespan (see Materials and Methods and Figure 5a ). First, we probed the quantity of the aggregates in the animals by means of an amyloid specific fluorescence probe, NIAD-4 20 (Figure 5b,c) . The results show that the administration of 10074-G5 resulted in a markedly lower aggregate load. We also monitored a number of phenotypic readouts of worm health, including body bends per minute, the extent of the bending motion, the speed of movement, and also the rate of paralysis. We found that 10074-G5 improved all of these characteristic behavioural parameters in worms expressing Aβ42 in a dose-dependent manner when compared to the untreated worms (Figure 5d,e) .
Taken together, these results demonstrate that the administration of 10074-G5 increases the health of this C. elegans model of Aβ42-mediated dysfunction and results in the presence of a smaller number of amyloid aggregates. These findings are consistent with the observation of the inhibition of the aggregation of Ab42 in the presence of 10074-G5 from the in vitro studies (Figures 3 and 4) . Furthermore, these results suggest that the combination of in silico, in vitro, and in vivo drug discovery methods holds promise for the identification of novel small molecules which inhibit the toxic behaviour of disease-related disordered proteins.
Conclusions
We have characterised the binding of the small molecule 10074-G5 to monomeric Ab42 using a combination of experimental approaches and integrative structural ensemble determination methods. The real-time, dose-dependent responses that we have observed in the BLI experiments demonstrate that 10074-G5 binds Aβ42 in its monomeric form (Figure 1b) . The NMR experiments and the metadynamic metainference simulations have illustrated that this binding is distinct from most small molecule interactions with structured proteins. In particular, we have observed that 10074-G5 does not bind to a single binding site, but rather binds transiently to many different sites (Figures 2, S7) . We have also found 10074-G5 induces Aβ42 to adopt many different conformations, keeping it disordered and more solvent-exposed (Figures 1) in the bound form. It appears that this interaction is largely entropic (Figure S2 ) and that some of this entropy arises from the increase in conformational entropy of Aβ42 (Figure S7c Additionally, we have characterised the effects of 10074-G5 on amyloid aggregation in vitro using a range of biophysical techniques and kinetic theory techniques. This analysis has revealed that as a result of the interaction of 10074-G5 with monomeric Aβ42, this small molecule also reduces the extent to which monomeric Ab42 contributes to aggregation, thereby effectively slowing down all microscopic aggregation rates. Our kinetic analysis of aggregation inhibition by monomer sequestration highlights that effective inhibition depends on the interplay of two combined parameters, namely a thermodynamic and kinetic one: . /[ ] and 34 [ ]/ 55 . Thus, for a small molecule with given affinity for monomeric Ab42, increasing 34 of small molecules for monomeric Ab42 represents a promising inhibitor optimisation strategy. We also anticipate future work to understand the relationship between 34 and the change in conformational entropy of Ab42 towards improved binders of monomeric disordered proteins.
Lastly, we show that 10074-G5 is highly effective at reducing the Aβ42 aggregate load and its associated toxicity in a C. elegans model of Alzheimer's disease.
Collectively, these results indicate the importance of developing a more detailed understanding of the interactions between disordered proteins and small molecules, which in turn could lead to the development of new therapeutic approaches for the many diseases in which such disordered proteins are involved. 
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Materials and Methods
BLI experiments.
A super streptavidin biosensor (ForteBio, Menlo Park, USA) was coated with 15 µg/ml monomeric N-terminally biotinylated Ab42 (AnaSpec, Fremont, USA) by overnight incubation a solution at 5 °C. Control biosensors were incubated with the same concentration of biocytin. The tips were then rinsed by incubation in buffer for 3 h at room temperature. The binding and dissociation between immobilized Ab42 and various concentrations of 10074-G5 was monitored for 200 s and 500 s respectively at 37 °C using an Octet Red96 (ForteBio, Menlo Park, USA). The binding of both 10074-G5 to a biocytin-functionalized tip and buffer to a Ab42functionlized biosensor were subtracted to account for non-specific binding and baseline drift, respectively. Data were analysed using GraphPad Prism 6. Dissociation data were first globally fit using a one-phase exponential decay to determine the 366 value. This value was then used as a constraint to determine the global 34 rate.
2D H N-BEST CON NMR experiments. 13 Metadynamic metainference simulations. To generate the structural ensembles, we employed an integrative approach that incorporates NMR chemical shift data into molecular dynamics simulations. To this end, we used metadynamic metainference, which compensates for the inaccuracies of the force field, accounts for errors in experimental data, and enhances sampling. 41, 42 All-atom metadynamic metainference simulations 41 of the unbound and bound form of Aβ42 were performed using GROMACS 2016.4 60 equipped with the open-source, community-developed PLUMED library 61 version 2.5 62 , the CHARMM22* force field 63 and TIP3P water model 64 . The initial conformation of Aβ42 was prepared as a linear peptide using PyMol 65 . A preliminary in vacuo molecular dynamics simulation was performed for 1 ns to collapse the extended conformation. This structure was solvated in a rhombic dodecahedron box with an initial volume of 362 nm 3 containing 11746 water molecules. The solvated system was minimised using the steepest descent algorithm with a target maximum force of 1000 kJ mol -1 nm -1 . A pool of 48 initial conformations was extracted from a preliminary 2 ns simulation at 600 K in the NVT ensemble. Equilibration was then performed in the NVT ensemble for 500 ps at 278 K using the Bussi-Donadio-Parrinello thermostat 66 and for 500 ps at 278 K in the NPT ensemble using Berendsen pressure coupling 67 with position restraints on heavy atoms.
Production runs were executed in the NPT ensemble at 278 K using the Parrinello-Rahman barostat 68 . A time step of 2 fs was used together with LINCS constraints on all bonds 69 . The van der Waals interactions were cut off at 1.2 nm, and the particle-mesh Ewald method was used for electrostatic interactions 70 . Bound simulations were performed as described above, using the starting structures obtained from the NVT equilibration at 600 K. The 10074-G5 molecule was added to a corner of the box and the system re-solvated with 11734 water molecules. The system was then minimized and equilibrated using the procedures described above. Preliminary parameters for 10074-G5 were taken from the CGenFF software 71, 72 , and those with any penalty were explicitly re-parameterised using the Force Field Toolkit 73 and Gaussian 09 74 (see SI and
Figure S4).
Chemical shifts were back-calculated at each time step using CamShift 75 (Figure S5) . Given that the error of the CamShift predictor is greater than the chemical shift perturbations upon addition of the compound, the same chemical shifts were used to restrain both the unbound and bound simulations. A Gaussian noise model with one error parameter per nucleus type was used in the metainference setup, along with an uninformative Jeffreys prior for each error parameter 41 (see SI). The metainference ensembles for the unbound and bound simulations were simulated using 48 replicas each.
Parallel bias metadynamics 76 with the well-tempered 77 and multiple-walkers 78 protocols was performed using a Gaussian deposition stride of 1 ps, an initial height of 1.2 kJ/mol, and bias factors of 24 and 49 for the unbound and bound simulations, respectively. In the unbound simulations, we used 6 collective variables (CVs) to enhance the conformational sampling of Aβ42 (see SI). In the bound simulations, we also included 14 CVs to enhance the conformational sampling of contacts between the compound and the peptide, and 4 CVs to enhance sampling of soft dihedrals in the small molecule (see SI). Unbound and bound simulations were run for an accumulated time of 27.8 and 28.2 µs, respectively until convergence was reached (see SI and Mass spectrometry. Monomeric Ab42 was diluted in the aggregation buffer (described above) to a concentration of 15 µM in the presence and absence of 30 µM 10074-G5. Samples were incubated overnight at 37 °C under quiescent conditions to mimic the aggregation experiments.
The samples were then spun down using an ultracentrifuge at 100,000 rpm for 1 h at 25 °C to separate the supernatant and pellet. 6 M GuHCl was used to dilute the supernatant by 50% with and resuspend the pellet. Samples were analysed by MALDI mass spectrometry at the Protein and Nucleic Acid Chemistry Facility (PNAC) at the Department of Biochemistry, University of Cambridge.
Dot-blot assay. Blotting was performed using the Ab42 sequence-specific antibody (W0-2, MABN10, Millipore, Burlington, USA). Samples were removed from a solution containing 2 µM Ab42 in the presence and absence of three-and ten-fold equivalence of 10074-G5. To ensure only the monomer was placed on the blots, samples were spun down using an ultracentrifuge at 100,000 rpm for 1 h at 25 °C using a TLA100 rotor. 2 µL of the supernatant were pipetted onto a nitrocellulose membrane (0.2 µM; Whatman). After drying, the membrane was blocked with 5% (w/v) bovine serum albumin (BSA) in phosphate-buffered saline (8 mM Na2HPO4, 15 mM 20 KH2PO4, 137 mM NaCl, 3 mM KCl, pH 7.4, PBS) overnight at 5 °C, followed by three 15 min washes with PBS at room temperature. The membrane was then immunised with a 1/1000 dilution of WO-2 anti-Ab antibody in PBS with 5% BSA overnight at 5 °C, followed by three 15 min washes with PBS at room temperature. The membrane was then incubated for 2 h at room temperature in PBS supplemented with 0.05% tween and an anti-mouse-Alexa Fluor 594 secondary antibody conjugate (ThermoFisher Scientific, Waltham, USA) at room temperature, and then washed three times with PBS supplemented with 0.05% tween. Fluorescence detection was performed using Typhoon Trio Imager (GE Healthcare, Chicago, IL, USA). Blots were quantified using ImageJ. Data were fit to a competitive binding equilibrium model between free monomers and fibrils (Eq. S13). In this model, monomers are either free, aggregated (i.e. part of a fibril), or bound to 10074-G5; the binding of the compound to the monomer is described by a single binding free energy. The binding of monomers to fibril ends is stronger compared to the binding of monomers to the inhibitor. The concentration of free monomer in equilibrium with amyloid fibrils (critical concentration) measured in our experiments is 89:;:8<= = 93 nM, consistent with other reports. 79 The equilibrium concentration of unreacted soluble monomer after ultracentrifugation measured at varying inhibitor concentration is fit to Eq. S13 withas a fitting parameter. This procedure yields -= 7 ± 1 µM, as shown in Figure 3e . Characterization of the interaction of 10074-G5 with stabilized oligomers. Stabilised oligomers were formed from Ab40 as previously described 56 Measurements were background subtracted against buffer alone in the absence and presence of compound. The protein content within samples was quantified using the sequence-specific WO-2 antibody (see Dot-blot assay). Similarly, the conformations of the oligomers in the presence and the absence of the compound was probed using the conformation-specific OC antibody 57 (AB2286, Millipore, Burlington, USA) using the protocols described above (see Dot-blot assay).
To determine if the oligomers had dissociated after the incubation in the presence of the compound, the samples were centrifuged for 15 min at 15 000 g. expresses the human full-length Aβ42 peptide in the muscle cells of the body wall. Raising the temperature above 20 °C at the L4 or adult stage causes paralysis due to Aβ42 aggregation in body wall muscle 36 . The N2 wild-type strain was used as a control 36, 58 .
Standard conditions were used for the propagation of C. elegans 36 ; the animals were synchronized by hypochlorite bleaching, hatched overnight in M9 (3 g/l KH2PO4, 6 g/l Na2HPO4, 5 g/l NaCl, 1M MgSO4) buffer, and subsequently cultured at 20 °C on nematode growth medium (NGM) (CaCl2 1mM, MgSO4 1mM, cholesterol 5 µg/ml, 250M KH2PO4 pH 6, Agar 17 g/L, NaCl 3g/l, casein 7.5g/l) plates seeded with the E. coli strain OP50. Saturated cultures of OP50 were grown by inoculating 50 mL of LB medium (tryptone 10g/l, NaCl 10g/l, yeast extract 5g/l) with OP50 and incubating the culture for 16 h at 37 °C. NGM plates were seeded with bacteria by adding 350 µl of saturated OP50 to each plate and leaving the plates at 20 °C for 2-3 days.
On day 3 after synchronization, the animals were placed on NGM plates containing 5-fluoro-2'deoxy-uridine (FUDR) (75 µM, unless stated otherwise) to inhibit the growth of offspring.
Aliquots of NGM media containing FUDR (75 µM) were autoclaved, poured, seeded with 350 µL OP50 culture, and grown overnight. After incubating for up to 3 days at room temperature, 2.2 mL aliquots of 10074-G5 dissolved in water at different concentrations were spotted atop the NGM plates. The plates were then placed in a sterile laminar flow hood at room temperature to dry. For the final experiments, worms were transferred onto the 10074-G5-seeded plates directly at larval stage L4 and they were exposed to 10075-G5 for the whole duration of the experiment.
To ensure that the presence of 10074-G5 did not affect the OP50 E. coli consumed by the C. elegans, we performed a growth assay of the E. coli directly from the NGM plates in the presence of 10074-G5 or DMSO after one day of incubation at 24 °C (Figure S15) . E. coli from the NGM plates were added to 4 mL of LB media and diluted to an optical density of 0.25. Then, 3 mL of this starter culture was added to 40 mL of sterile LB media, which was incubated at 37 °C and shaking at 180 RPM. Optical density measurements were collected every 30 minutes and the experiment was performed in duplicate.
All C. elegans populations were cultured at 20 °C and developmentally synchronized from a 4 h egg-lay. At 64-72 h post egg-lay (time zero) individuals were transferred to FUDR plates, cultured at 24°C to stimulate aggregation, and body movements were assessed over the times indicated. At different ages, the animals were washed off the agar plates with M9 buffer and spread over an OP50 un-seeded 9 cm plate. The swimming worms were visualized by using a high-performance imaging lens and a machine vision camera, after which their movements were recorded at a high number of frames per second (fps) for 30 s or 1 min 80, 81 . Body bends were then quantified using a tracking algorithm 81, 82 . Briefly, after an initial background subtraction, a second (nonadaptive) thresholding procedure was performed and worms were identified and labelled. The eccentricity, a measure of the ratio of the minor and major ellipse axes, of each tracked worm was then used to estimate the worm bending as a function of time 81, 82 . The total health was calculated by summing the mobility, speed, bend measure, and viability of the worms 81, 82 . Total health values were normalized using the values of the control worms. At least 150 animals were examined per condition, unless stated otherwise. All experiments were carried out in triplicate and the data from one representative experiment are shown in Figure 5 . Control experiments to test the effects of 10074-G5 on the movement of N2 wild type C. elegans are shown in Figure S16 . Two-tailed Student's t tests (unpaired) were used to calculate P values.
Statistical analysis was performed using the GraphPad Prism 6 software.
To stain the aggregates within the C. elegans, live transgenic animals were incubated with 1 µM NIAD-4 (0.1% DMSO in M9 buffer) for 4 h at room temperature 20 . After staining, animals were allowed to recover on NGM plates for about 24 h to allow destaining via normal metabolism.
Stained animals were mounted on 2% agarose pads containing 40 mM NaN3 as an anesthetic on glass microscope slides for imaging. Images were captured with a Zeiss Axio Observer D1 fluorescence microscope (Carl Zeiss Microscopy GmbH, Jena, Germany) with a 20 × objective and a 49004 ET-CY3/TRITC filter (Chroma Technology Corp, Bellows Falls, USA). Quantification of the relative / ? intensities from (c) shows that the peptide amide groups are more exposed to solvent in the presence of 10074-G5. Arrows highlight regions along the sequence in which signals are detectable in the absence of the compound, but not in its presence, thus suggesting that 10074-G5 increases the solvent exposure of specific regions of Aβ42. (Figure S16) .
